about
Fourteen years' follow-up of an autoimmune patient lacking the CD3 gamma subunit of the T-lymphocyte receptorObstetric and offspring risks of women's morbid conditions linked to prior anticancer treatmentsBeneficial effects of dithiothreitol on relative levels of glutathione S-transferase activity and thiols in oocytes, and cell number, DNA fragmentation and allocation at the blastocyst stage in the mouse.Estradiol stimulates vasodilatory and metabolic pathways in cultured human endothelial cells.SNPs in bone-related miRNAs are associated with the osteoporotic phenotype.Changes in sex ratio from fertilization to birth in assisted-reproductive-treatment cycles.Absence of long-term effects of reproduction on longevity in the mouse modelAssociations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.Deficiencies in reporting results of lesbians and gays after donor intrauterine insemination and assisted reproductive technology treatments: a review of the first emerging studies.The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis?Isoflavones and cardiovascular disease.Transient regional osteoporosis.Assisted reproductive technology results: why are live-birth percentages so low?Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture.Potential risks to offspring of intrauterine exposure to maternal age-related obstetric complications.Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line.The role of CD40 and CD40L in bone mineral density and in osteoporosis risk: A genetic and functional study.A novel CD18 genomic deletion in a patient with severe leucocyte adhesion deficiency: a possible CD2/lymphocyte function-associated antigen-1 functional association in humans.Progestogens stimulate prostacyclin production by human endothelial cells.Relationship between PTH, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women.Bone turnover markers and PTH levels in surgical versus natural menopause.Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women.No effect of Cimicifuga racemosa extract on serum interleukin-6 levels and prostacyclin production by human endothelial cells.Gene-gene interaction between CD40 and CD40L reduces bone mineral density and increases osteoporosis risk in women.Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.The Asn19Lys substitution in the osteoclast inhibitory lectin (OCIL) gene is associated with a reduction of bone mineral density in postmenopausal women.Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice.Replication study of three functional polymorphisms associated with bone mineral density in a cohort of Spanish women.Note of clarification: Potential risks to offspring of intrauterine exposure to maternal age-related obstetric complications.A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women.Serum Circulating MicroRNAs as Biomarkers of Osteoporotic Fracture.Gene expression profile induced by ovariectomy in bone marrow of mice: a functional approach to identify new candidate genes associated to osteoporosis risk in women.Long-term effects of delayed fatherhood in mice on postnatal development and behavioral traits of offspring.Delayed fatherhood in mice decreases reproductive fitness and longevity of offspring.Surgical planning after sleep versus awake techniques in patients with obstructive sleep apnea.Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women.Progestogens reduce thromboxane production by cultured human endothelial cells.Missense mutations in codon 225 of ornithine transcarbamylase (OTC) result in decreased amounts of OTC protein: a hypothesis on the molecular mechanism of the OTC deficiencyDemonstration of the spf-ash mutation in Spanish patients with ornithine transcarbamylase deficiency of moderate severityIdentification of a cytogenetic deletion and of four novel mutations (Q69X, I172F, G188V, G197R) affecting the gene for ornithine transcarbamylase (OTC) in Spanish patients with OTC deficiency
P50
Q24290844-343C03BA-128C-4C35-9588-358206AD6A93Q26744055-F770641A-D2DD-4FFC-84C2-452C59F816BFQ33267488-7E8ACDBC-C8DE-4B18-8889-BA9FBA41A86DQ33518553-DF2EAA4B-7DAE-4E1F-9DC6-E8A7DB3BE9D0Q33674490-12D0C4BC-5B3D-434F-99EF-6F62AA4564E7Q33836615-4FE9E918-7D5D-43DC-9883-C648C11208C1Q34143948-9A1F3BD1-DA74-4DA5-9D2A-4CCAE0E9F6A5Q34558902-AB41EDAD-DB49-448F-A2EF-31CD4BC07DF0Q35669513-AD46D873-3FD3-4048-B17F-0DC50890D3A9Q37470341-B1644C37-C189-462E-98F8-390A928ECA80Q37781551-DE54F8E2-133A-46D3-B1BF-B324BAB07105Q38192280-49DE197B-6006-43B4-8488-0D7EF3F35D1FQ38210367-A6C4EEF5-DF4F-4607-AF0F-6018F3B679C0Q38248243-393D4C4C-6036-4825-8E4C-01278F84F858Q39508677-5E526503-578C-4E63-B803-926EAD3A9D32Q39972204-4CA7C9CE-F525-4995-B200-7B42BADA0B60Q40347821-B102CE57-1332-4398-A3ED-33D82C49272BQ40774385-7CB50058-E900-453A-8042-A6AE224DF6F4Q42474826-737BD086-FAAB-4846-8FB8-FBEE1040A754Q44445621-CB49A1B7-3714-4A96-891A-CBADE46F26E2Q44675394-26ADE1E1-5292-497F-A978-F266E13CC4D0Q45928925-6B05BF68-A702-43B6-9385-5D10D280AD47Q46114156-522554D8-F3B0-4DE4-92F7-1F4D22BFD49FQ46205454-8EA4E125-D1F0-49C8-8C8E-B268B68F0D29Q46513379-E7FD9E5F-DFC4-4D55-8ADC-33069F3ED703Q46606050-029B2B43-C669-4C85-9AA0-3DE90103B3D8Q46925191-3F2167AB-229C-43E4-B96C-BAD847E22286Q46946218-95DC3E6B-FEAD-47E5-BCDE-DAF69314B04DQ47183282-29D31DBB-96D4-4AA7-98E7-3F8C4ECB1360Q47217022-357F1A33-A4CC-4589-8F99-F10D7396F7CEQ47396727-554CCD38-11D6-4176-8CB7-F1B0CC52E044Q47645353-69BC8B46-05E4-4E27-83AE-7CF2C4FDF6F0Q47649695-1FB8D6D3-858D-4062-B7AC-C04281E4FEFAQ47649706-A225BE16-DA9C-4DC1-8FC0-B35AB14526BFQ48134064-BF5C1F08-0020-4F23-88E3-9664BAECCA43Q50782648-A6DC2A74-FB5C-4157-8162-B035B7D13E12Q54429618-11EC6A25-7A7A-4073-820B-1E6CE4862D81Q57563284-D6F9967B-1903-4664-8BBB-338E448A22CDQ57563300-8B8B8776-AC09-42AE-981E-C11BBFBC459BQ73032499-5CE30069-62B2-4FBD-97C4-A92D69F4F219
P50
description
researcher
@en
name
M A García-Pérez
@en
M A García-Pérez
@nl
type
label
M A García-Pérez
@en
M A García-Pérez
@nl
prefLabel
M A García-Pérez
@en
M A García-Pérez
@nl
P106
P31
P496
0000-0002-0626-7502